Background: Reducing mutant huntingtin (mHTT) in neurons may be a therapy for Huntington’s disease (HD). Elevating NUB1 protein reduced mHTT levels in cell and fly models of HD through a proteasome dependent mechanism.
Objective: To examine the effects of augmenting NUB1 in HD mouse striatum on mHTT levels.
Methods: Striata of HDQ175/Q7 mice were injected at 3 months of age with recombinant AAV2/9 coding for NUB1 or GFP under the control of the neuron specific human synapsin 1 promoter and examined 6 months post-injection for levels of huntingtin, the striatal markers DARPP32 and PDE10A, the astrocyte marker GFAP, and the autophagy and mHTT aggregate marker P62 using immunolabeling of brain sections and Western blot assay of striatal subcellular fractions.
Results: By Western blot human HD brain had only one of the two variants of NUB1 present in human control brain. In striatum of WT and HD mice NUB1 was localized in medium size neurons and enriched in the nucleus of large neurons. In the striatum of NUB1 injected HD mice, there was widespread neuronal distribution of exogenous NUB1 labeling and protein levels were ∼2.5-fold endogenous levels. DARPP32 and GFAP distribution and levels were unchanged but PDE10A levels were lower in crude homogenates and P62 was increased in nuclear enriched P1 fractions. Elevating NUB1 did not change levels of full-length mHTT or the number and size of mHTT (S830) positive nuclear inclusions.
Conclusion: Findings suggest that increasing NUB1 protein in striatal neurons of HDQ175/Q7 mice in vivo may be relatively safe but is ineffective in reducing mHTT. Increased NUB1 expression in HD striatum alters PDE10A and P62 which are known to be influenced by mHTT.
GuX, GreinerER, MishraR, KodaliR, OsmandA, FinkbeinerS, SteffanJS, ThompsonLM, WetzelR, YangXW. Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron. 2009;64(6):828–840.
6.
SontagEM, JoachimiakLA, TanZ, TomlinsonA, HousmanDE, GlabeCG, PotkinSG, FrydmanJ, ThompsonLM. Exogenous delivery of chaperonin subunit fragment ApiCCT1 modulates mutant Huntingtin cellular phenotypes. Proc Natl Acad Sci U S A. 2013;110(8):3077–3082.
WuJ, QiL, WangY, KegelKB, YoderJ, DifigliaM, QinZ, LinF. The regulation of N-terminal Huntingtin (Htt552) accumulation by Beclin1. Acta Pharmacol Sin. 2012;33(6):743–751.
9.
KimW, SeoH. Baclofen, a GABAB receptor agonist, enhances ubiquitin-proteasome system functioning and neuronal survival in Huntington’s disease model mice. Biochem Biophys Res Commun. 2014;443(2):706–711.
10.
Schipper-KromS, JuenemannK, JansenAH, WiemhoeferA, van den NieuwendijkR, SmithDL, HinkMA, BatesGP, OverkleeftH, OvaaH, ReitsE. Dynamic recruitment of active proteasomes into polyglutamine initiated inclusion bodies. FEBS Lett. 2014;588(1):151–159.
11.
KitoK, YehETH, KamitaniT. NUB1, a NEDD8-interacting protein, is induced by interferon and down-regulates the NEDD8 expression. J Biol Chem. 2001;276(23):20603–20609.
12.
TanakaT, KawashimaH, YehETH, KamitaniT. Regulation of the NEDD8 conjugation system by a splicing variant, NUB1L. J Biol Chem. 2003;278(35):32905–32913.
13.
TanjiK, TanakaT, MoriF, KitoK, TakahashiH, WakabayashiK, KamitaniT. NUB1 suppresses the formation of Lewy body-like inclusions by proteasomal degradation of synphilin-1. Am J Pathol. 2006;169(2):553–565.
14.
TanjiK, MoriF, KitoK, KakitaA, MimuraJ, ItohK, TakahashiH, KamitaniT, WakabayashiK. Synphilin-1-binding protein NUB1 is colocalized with nonfibrillar, proteinase K-resistant α-synuclein in presynapses in Lewy body disease. J Neuropathol Exp Neurol. 2011;70(10):879–889.
15.
RichetE, PoolerAM, RodriguezT, NovoselovSS, SchmidtkeG, GroettrupM, HangerDP, CheethamME, Spuy van derJ. NUB1 modulation of GSK3β reduces tau aggregation. Hum Mol Genet. 2012;21(24):5254–5267.
16.
LuB, Al-RamahiI, ValenciaA, WangQ, BerenshteynF, YangH, Gallego-FloresT, IchchoS, LacosteA, HildM, DiFigliaM, BotasJ, PalacinoJ. Identification of NUB1 as a suppressor of mutant Huntingtin toxicity via enhanced protein clearance. Nat Neurosci. 2013;16(5):562–570.
KimYJ, SappE, CuiffoBG, SobinL, YoderJ, KegelKB, QinZ-H, DetloffP, AroninN, DiFigliaM. Lysosomal proteases are involved in generation of N-terminal huntingtin fragments. Neurobiol Dis. 2006;22(2):346–356.
20.
VodickaP, LimJ, WilliamsDT, KegelKB, ChaseK, ParkH, MarchioniniD, WilkinsonS, MeadT, BirchH, YatesD, LyonsK, DominguezC, BeconiM, YueZ, AroninN, DiFigliaM. Assessment of chloroquine treatment for modulating autophagy flux in brain of WT and HD mice. J Huntingtons Dis. 2014;3(2):159–174.
21.
DiFigliaM, SappE, ChaseK, SchwarzC, MeloniA, YoungC, MartinE, VonsattelJ-P, CarrawayR, ReevesSA, BoyceFM, AroninN. Huntingtin is a cytoplasmic proteinassociated with vesicles in human and rat brain neurons. Neuron. 1995;14(5):1075–1081.
22.
LandlesC, SathasivamK, WeissA, WoodmanB, MoffittH, FinkbeinerS, SunB, GafniJ, EllerbyLM, TrottierY, RichardsWG, OsmandA, PaganettiP, BatesGP. Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J Biol Chem. 2010;285, 8808–8823.
23.
ShuSY, JuG, FanLZ. The glucose oxidase-DAB-nickel method in peroxidase histochemistry of the nervous system. Neurosci Lett. 1988;85(2):169–171.
24.
OsmandAP, BerthelierV, WetzelR. Imaging polyglutamine deposits in brain tissue. In: Enzymology B-M in, ed. Academic Press; 2006 [cited 2016 Jan 8]. p. 106–122. Available from: http://www.sciencedirect.com/science/article/pii/S008X
25.
R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Viena, Austria. ISBN 3-900051-07-0; 2015.
GrolemundG, SpinuV, WickhamH, LyttleJ, ConstiganI, LawJ, MitarotondaD, LarmarangeJ, BoiserJ, LeeCH. lubridate: Make Dealing with Dates a Little Easier [Internet]. 2015 [cited Feb 16]. Available from: https://cran.r-project.org/web/packages/lubridate/index.html
HebbALO, RobertsonHA, Denovan-WrightEM. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington’s disease transgenic mice prior to the onset of motor symptoms. Neuroscience. 2004;123(4):967–981.
33.
PankivS, ClausenTH, LamarkT, BrechA, BruunJ-A, OutzenH, ØvervatnA, BjørkøyG, JohansenT. p62/SQSTM1 Binds Directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem. 2007;282(33):24131–24145.
34.
NagaokaU., KimK.,
JanaNR.,
DoiH.,
MaruyamaM., MitsuiK.,
OyamaF.,
NukinaN.. Increased expression of p62 in expanded polyglutamine-expressing cells and its association with polyglutamine inclusions. J Neurochem. 2004;91(1):57–68.
35.
RuéL, López-SoopG, GelpiE, Martínez-VicenteM, AlberchJ, Pérez-NavarroE. Brain region- and age-dependent dysregulation of p62 and NBR1 in a mouse model of Huntington’s disease. Neurobiol Dis. 2013;52(0):219–228.
36.
KurosawaM, MatsumotoG, KinoY, OkunoM, Kurosawa-YamadaM, WashizuC, TaniguchiH, NakasoK, YanagawaT, WarabiE, ShimogoriT, SakuraiT, HattoriN, NukinaN. Depletion of p62 reduces nuclear inclusions and paradoxically ameliorates disease phenotypes in Huntington’s model mice. Hum Mol Genet. 2015;24(4):1092–1105.
37.
TanjiK, MikiY, MaruyamaA, MoriF, MimuraJ, ItohK, KamitaniT, WakabayashiK. The role of NUB1 in α-synuclein degradation in Lewy body disease model mice. Biochem Biophys Res Commun. 2016;470(3):635–642.
38.
LiJ, MaW, LiH, HouN, WangX, KimI, LiF, SuH. NEDD8 Ultimate Buster 1 Long (NUB1L) Protein suppresses atypical neddylation and promotes the proteasomal degradation of misfolded proteins. J Biol Chem. 2015;290(39):23850–23862.
39.
SeoH, SonntagK-C, IsacsonO. Generalized brain and skin proteasome inhibition in Huntington’s disease. Ann Neurol. 2004;56(3):319–328.
NishiA, KuroiwaM, MillerDB, O’CallaghanJP, BateupHS, ShutoT, SotogakuN, FukudaT, HeintzN, GreengardP, SnyderGL. Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J Neurosci. 2008;28(42):10460–10471.
42.
NiccoliniF, HaiderS, MarquesTR, MuhlertN, TziortziAC, SearleGE, NatesanS, PicciniP, KapurS, RabinerEA, GunnRN, TabriziSJ, PolitisM. Altered PDE10A expression detectable early before symptomatic onset in Huntington’s disease. Brain. 2015;138(10):3016–3029.
43.
HuH, McCawEA, HebbALO, GomezGT, Denovan-WrightEM. Mutant huntingtin affects the rate of transcription of striatum-specific isoforms of phosphodiesterase 10A. Eur J Neurosci. 2004;20(12):3351–3363.
44.
GiampàC, LaurentiD, AnzilottiS, BernardiG, MennitiFS, FuscoFR. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington’s disease. PLoS One. 2010;5(10):e13417.
45.
MenalledLB, KudwaAE, MillerS, FitzpatrickJ, Watson-JohnsonJ, KeatingN, RuizM, MushlinR, AlosioW, McConnellK, ConnorD, MurphyC, OakeshottS, KwanM, BeltranJ, GhavamiA, BrunnerD, ParkLC, RambozS, HowlandD. Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington’s disease: ZQ175. PLoS One. 2012;7(12):e49838.
46.
CartyN, BersonN, TillackK, ThiedeC, ScholzD, KottigK, SedaghatY, GabrysiakC, YohrlingG, von der KammerH, EbnethA, MackV, Munoz-SanjuanI, KwakS. Characterization of HTT inclusion size, location, and timing in the zQ175 mouse model of Huntington’s Disease: An in vivo high-content imaging study. PLoS One. 2015;10(4):e0123527.
